Simpson Jr, S and Taylor, B and Dwyer, DE and Taylor, J and Blizzard, L and Ponsonby, AL and Pittas, F and Dwyer, T and Van der Mei, I, Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis, Multiple sclerosis journal, 18, (6) pp. 799-806. ISSN 1477-0970 (2012) [Refereed Article]
Copyright 2012 SAGE
Background: Some of the strongest associations with MS onset are for human herpesviruses, particularly Epstein–Barr virus (EBV) and human herpesvirus 6 (HHV-6). Their role in MS clinical course is less clear, however.
Methods: Prospective cohort of 198 persons with clinically definite MS, followed 2002–5, and serum samples obtained from all subjects at study entry to measure anti-HHV-6 and anti-EBV (Epstein–Barr nuclear antigen [EBNA] and viral capsid antigen [VCA]) IgG titers. Association with relapse evaluated using survival analysis; association with disability/progression evaluated using linear regression or multilevel mixed-effects linear regression.
Results: For the 145 persons with relapsing–remitting MS followed beyond one review, anti-HHV-6 IgG titer was positively associated with the hazard of relapse with a dose-dependent trend (p = 0.003), not affected by adjustment for anti-EBV IgG titers, neither of which were independently associated with relapse. There was no significant association between anti-human herpesvirus IgG titers and baseline-measured disability scores, or change in disability scores; however, anti-HHV-6 IgG titers were 2.8 times higher among progressive-course females than progressive-course males.
Discussion: These findings suggest that, in addition to a potential etiological role in MS, HHV-6 infection or the immune response to HHV-6 antigens may have an effect on the risk of MS relapses and possibly on progressive courses of MS. The observed effect was directly related to anti-HHV-6 IgG titers and may indicate that either HHV-6 infection or factors associated with an altered humoral immune response to HHV-6 may have an effect on MS clinical course. Anti-HHV-6 IgG titer may be a useful prognostic factor in relapsing–remitting MS clinical course.
|Item Type:||Refereed Article|
|Keywords:||epidemiology, Epstein–Barr virus, human herpesvirus 6, multiple sclerosis|
|Research Division:||Medical and Health Sciences|
|Research Group:||Public Health and Health Services|
|Objective Group:||Clinical Health (Organs, Diseases and Abnormal Conditions)|
|Objective Field:||Nervous System and Disorders|
|Author:||Simpson Jr, S (Dr Steve Simpson JR)|
|Author:||Taylor, B (Professor Bruce Taylor)|
|Author:||Blizzard, L (Professor Leigh Blizzard)|
|Author:||Pittas, F (Dr Fotini Pittas)|
|Author:||Van der Mei, I (Associate Professor Ingrid van der Mei)|
|Year Published:||2012 (online first 2011)|
|Funding Support:||National Health and Medical Research Council (490020)|
|Web of Science® Times Cited:||17|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page